The US Food and Drug Administration (FDA) process for quantifying the risk of under-age use of next-generation products (NGPs) could be fuelling the illicit market because so many NGPs are being refused authorisation ...
Sign up to our newsletter
Stay up-to-date with key regulatory news and receive complimentary data on a regular basis.